BR0209484A - Potenciação de efeitos terapêuticos de ácidos graxos - Google Patents
Potenciação de efeitos terapêuticos de ácidos graxosInfo
- Publication number
- BR0209484A BR0209484A BR0209484-3A BR0209484A BR0209484A BR 0209484 A BR0209484 A BR 0209484A BR 0209484 A BR0209484 A BR 0209484A BR 0209484 A BR0209484 A BR 0209484A
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic effects
- potentiation
- fatty acids
- fatty acid
- cox
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 3
- 229930195729 fatty acid Natural products 0.000 title abstract 3
- 239000000194 fatty acid Substances 0.000 title abstract 3
- 150000004665 fatty acids Chemical class 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101710159002 L-lactate oxidase Proteins 0.000 abstract 1
- 101710153103 Long-chain-fatty-acid-CoA ligase FadD13 Proteins 0.000 abstract 1
- 101710153099 Long-chain-fatty-acid-CoA ligase FadD15 Proteins 0.000 abstract 1
- 101710154693 Medium/long-chain-fatty-acid-CoA ligase FadD17 Proteins 0.000 abstract 1
- 101710141422 Medium/long-chain-fatty-acid-CoA/3-oxocholest-4-en-26-oate-CoA ligase Proteins 0.000 abstract 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 abstract 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 1
- 235000004626 essential fatty acids Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
"POTENCIAçãO DE EFEITOS TERAPêUTICOS DE áCIDOS GRAXOS". A presente invenção refere-se a administração oral de um ácido graxo essencial, preferivelmente ácido eicosapentaenóico, em uma pureza definida junto com um inibidor de COX-1 ou COX-2 ou LOX ou uma ou mais das enzimas FACL proporciona resultados terapêuticos aperfeiçoados sobre administração do ácido graxo sozinho.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0111282.0A GB0111282D0 (en) | 2001-05-09 | 2001-05-09 | Potentiation of therapeutic effects of fatty acids |
PCT/GB2002/002145 WO2002089787A1 (en) | 2001-05-09 | 2002-05-09 | Potentiation of therapeutic effects of fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209484A true BR0209484A (pt) | 2004-07-06 |
Family
ID=9914264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209484-3A BR0209484A (pt) | 2001-05-09 | 2002-05-09 | Potenciação de efeitos terapêuticos de ácidos graxos |
Country Status (27)
Country | Link |
---|---|
US (2) | US20020169209A1 (pt) |
EP (1) | EP1392276B1 (pt) |
JP (1) | JP4415243B2 (pt) |
KR (1) | KR20030096355A (pt) |
CN (1) | CN1638753A (pt) |
AT (1) | ATE349207T1 (pt) |
AU (1) | AU2002255164B2 (pt) |
BR (1) | BR0209484A (pt) |
CA (1) | CA2446363A1 (pt) |
CZ (1) | CZ20032978A3 (pt) |
DE (1) | DE60217103T2 (pt) |
DK (1) | DK1392276T3 (pt) |
EE (1) | EE200300549A (pt) |
ES (1) | ES2279864T3 (pt) |
GB (1) | GB0111282D0 (pt) |
HK (1) | HK1059386A1 (pt) |
HU (1) | HUP0400010A2 (pt) |
IL (1) | IL158678A (pt) |
IS (1) | IS7004A (pt) |
MX (1) | MXPA03010185A (pt) |
NO (1) | NO20034920D0 (pt) |
PL (1) | PL367508A1 (pt) |
RU (1) | RU2003133449A (pt) |
SK (1) | SK13652003A3 (pt) |
UA (1) | UA79744C2 (pt) |
WO (1) | WO2002089787A1 (pt) |
ZA (1) | ZA200308417B (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
ITMI20020731A1 (it) * | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3 |
NZ539624A (en) | 2002-09-27 | 2008-08-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
US8617617B2 (en) * | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
GB0301701D0 (en) * | 2003-01-24 | 2003-02-26 | Ensay Ltd | Psoriasis and Eicosapentaenoic acid |
US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
KR20060123329A (ko) * | 2003-12-16 | 2006-12-01 | 오노 야꾸힝 고교 가부시키가이샤 | 월경 곤란증의 예방 및/또는 치료제 |
ES2247939B1 (es) * | 2004-08-19 | 2007-04-01 | Fernando Jose Garcia Fructuoso | Suplemento alimenticio basado en la utilizacion de acidos grasos omega-3 (dha-epa) para el tratamiento del sindrome de fatiga cronica. |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP5491697B2 (ja) * | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物 |
GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
JP2008526894A (ja) * | 2005-01-10 | 2008-07-24 | レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | Cox阻害剤および5−lox阻害剤の活性を助けるための可溶性エポキシドヒドロラーゼの阻害剤の使用 |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
EP1852114B1 (en) * | 2005-02-14 | 2019-09-18 | Suntory Holdings Limited | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
JP5566603B2 (ja) | 2005-05-23 | 2014-08-06 | マサチューセッツ インスティテュート オブ テクノロジー | Pufaを含有する組成物及びそれを使用した方法 |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
CA2570763C (en) | 2005-07-08 | 2011-08-23 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing onset of cardiovascular events |
US20070042008A1 (en) * | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
KR100697352B1 (ko) * | 2006-01-03 | 2007-03-20 | 신승종 | 층간 소음 저감 구조체 |
CN101365438A (zh) * | 2006-02-07 | 2009-02-11 | 持田制药株式会社 | 预防中风复发的组合物 |
EP2004161B8 (en) * | 2006-04-12 | 2013-04-17 | Unilever PLC | Oral composition comprising dha and genistein for enhancing skin properties |
EP2004169B1 (en) * | 2006-04-12 | 2012-08-08 | Unilever PLC | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
ES2393212T3 (es) * | 2006-04-12 | 2012-12-19 | Unilever N.V. | Composición oral con un efecto antienvejecimiento sobre la piel |
KR100787765B1 (ko) | 2006-11-07 | 2007-12-24 | 고려대학교 산학협력단 | 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물 |
WO2008081989A1 (ja) | 2006-12-28 | 2008-07-10 | Suntory Holdings Limited | 神経再生剤 |
US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
DK2121576T3 (en) | 2007-02-15 | 2016-02-15 | Ct De Rech Sur Les Biotechnologies Marine | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
CA2639412A1 (en) * | 2007-09-11 | 2009-03-11 | Universite Laval | Prostaglandin e2 modulation and uses thereof |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
WO2009059306A1 (en) | 2007-11-02 | 2009-05-07 | Massachusetts Institute Of Technology | Uridine dietary supplementation compliance methods and use thereof |
WO2009099886A1 (en) * | 2008-01-31 | 2009-08-13 | Monsanto Technology Llc | Methods of improving dha deposition and related function and/or development |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US9216224B2 (en) | 2010-03-05 | 2015-12-22 | Catabasis Pharmaceuticals, Inc. | Fatty acid COX inhibitor derivatives and their uses |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013072767A1 (en) | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US10639313B2 (en) | 2017-09-01 | 2020-05-05 | Ndsu Research Foundation | Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation |
CN111971041A (zh) | 2018-02-07 | 2020-11-20 | Scf制药股份有限公司 | 多不饱和脂肪酸单甘油酯、组合物、方法及其用途 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
AU2019264159A1 (en) | 2018-05-03 | 2020-12-24 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
GB8507058D0 (en) * | 1985-03-19 | 1985-04-24 | Efamol Ltd | Pharmaceutical & dietary compositions |
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US5225441A (en) * | 1987-06-18 | 1993-07-06 | Block Drug Company, Inc. | Treatment of periodontal disease |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
US5409955A (en) * | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
US5840715A (en) * | 1995-12-11 | 1998-11-24 | Inholtra Investment Holdings & Trading, N.V. | Dietary regimen of nutritional supplements for relief of symptoms of arthritis |
US5912006A (en) * | 1996-08-28 | 1999-06-15 | Eboc, Inc. | Compositions and methods for alleviating discomforting menstrual pain |
AU3846801A (en) * | 2000-02-16 | 2001-08-27 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
-
2001
- 2001-05-09 GB GBGB0111282.0A patent/GB0111282D0/en not_active Ceased
-
2002
- 2002-04-30 US US10/134,501 patent/US20020169209A1/en not_active Abandoned
- 2002-05-09 AU AU2002255164A patent/AU2002255164B2/en not_active Expired - Fee Related
- 2002-05-09 CZ CZ20032978A patent/CZ20032978A3/cs unknown
- 2002-05-09 AT AT02724472T patent/ATE349207T1/de not_active IP Right Cessation
- 2002-05-09 SK SK1365-2003A patent/SK13652003A3/sk not_active Application Discontinuation
- 2002-05-09 IL IL158678A patent/IL158678A/en not_active IP Right Cessation
- 2002-05-09 EP EP02724472A patent/EP1392276B1/en not_active Expired - Lifetime
- 2002-05-09 CA CA002446363A patent/CA2446363A1/en not_active Abandoned
- 2002-05-09 PL PL02367508A patent/PL367508A1/xx not_active Application Discontinuation
- 2002-05-09 BR BR0209484-3A patent/BR0209484A/pt not_active Application Discontinuation
- 2002-05-09 KR KR10-2003-7014417A patent/KR20030096355A/ko not_active Application Discontinuation
- 2002-05-09 MX MXPA03010185A patent/MXPA03010185A/es active IP Right Grant
- 2002-05-09 WO PCT/GB2002/002145 patent/WO2002089787A1/en active IP Right Grant
- 2002-05-09 CN CNA028125800A patent/CN1638753A/zh active Pending
- 2002-05-09 RU RU2003133449/15A patent/RU2003133449A/ru not_active Application Discontinuation
- 2002-05-09 DK DK02724472T patent/DK1392276T3/da active
- 2002-05-09 HU HU0400010A patent/HUP0400010A2/hu unknown
- 2002-05-09 ES ES02724472T patent/ES2279864T3/es not_active Expired - Lifetime
- 2002-05-09 DE DE60217103T patent/DE60217103T2/de not_active Expired - Fee Related
- 2002-05-09 EE EEP200300549A patent/EE200300549A/xx unknown
- 2002-05-09 JP JP2002586922A patent/JP4415243B2/ja not_active Expired - Fee Related
- 2002-09-05 UA UA2003119997A patent/UA79744C2/uk unknown
-
2003
- 2003-10-29 ZA ZA200308417A patent/ZA200308417B/en unknown
- 2003-10-30 IS IS7004A patent/IS7004A/is unknown
- 2003-11-04 NO NO20034920A patent/NO20034920D0/no not_active Application Discontinuation
-
2004
- 2004-03-26 HK HK04102246A patent/HK1059386A1/xx not_active IP Right Cessation
-
2005
- 2005-05-13 US US11/128,401 patent/US20050209329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020169209A1 (en) | 2002-11-14 |
DE60217103T2 (de) | 2007-08-16 |
UA79744C2 (en) | 2007-07-25 |
ZA200308417B (en) | 2004-05-24 |
NO20034920D0 (no) | 2003-11-04 |
IL158678A (en) | 2008-06-05 |
EP1392276A1 (en) | 2004-03-03 |
IS7004A (is) | 2003-10-30 |
GB0111282D0 (en) | 2001-06-27 |
HK1059386A1 (en) | 2004-07-02 |
CN1638753A (zh) | 2005-07-13 |
JP2004537514A (ja) | 2004-12-16 |
MXPA03010185A (es) | 2004-03-16 |
DE60217103D1 (de) | 2007-02-08 |
IL158678A0 (en) | 2004-05-12 |
KR20030096355A (ko) | 2003-12-24 |
DK1392276T3 (da) | 2007-05-07 |
HUP0400010A2 (hu) | 2004-04-28 |
ATE349207T1 (de) | 2007-01-15 |
EP1392276B1 (en) | 2006-12-27 |
PL367508A1 (en) | 2005-02-21 |
WO2002089787A1 (en) | 2002-11-14 |
EE200300549A (et) | 2004-02-16 |
US20050209329A1 (en) | 2005-09-22 |
RU2003133449A (ru) | 2005-01-20 |
AU2002255164B2 (en) | 2008-09-11 |
ES2279864T3 (es) | 2007-09-01 |
CZ20032978A3 (cs) | 2004-09-15 |
JP4415243B2 (ja) | 2010-02-17 |
CA2446363A1 (en) | 2002-11-14 |
SK13652003A3 (sk) | 2004-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209484A (pt) | Potenciação de efeitos terapêuticos de ácidos graxos | |
BR0112073A (pt) | Combinações terapêuticas de ácidos graxos | |
BR0209749A (pt) | Coenzima q e epa ou outro ácido graxo essencial | |
PT1152755E (pt) | Acidos gordos essenciais destinados a prevencao de acidentes cardio-vasculares | |
WO2006086108A3 (en) | Use of inhibitors of soluble epoxide hydrolase to synergize activity of cox and 5-lox inhibitors | |
BR0213213A (pt) | composições farmacêuticas pró-micela | |
NO20022058D0 (no) | Farmasöytiske sammensetninger | |
YU59303A (sh) | Esencijalne n-3 masne kiseline u lečenju srčane insuficijencije i manjkavosti rada srca | |
PA8469401A1 (es) | Derivados biciclicos del acido hidroxamico | |
ATE433989T1 (de) | Pharmazeutisch wirksame uridinester | |
PT1423168E (pt) | Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico | |
DE60031940D1 (de) | Selbstbräunende zusammensetzungen , die dha und propolis-extrakt enthalten | |
HUP0000137A2 (hu) | Szabályozott hatóanyag-felszabadulású analgetikumot tartalmazó gyógyszerkészítmény | |
KR970025615A (ko) | 암 전이 억제제 | |
BR9812553A (pt) | Formulação medicamentosa com liberação de substância ativa controlada | |
PT1425005E (pt) | Composicao farmaceutica que compreende lumiracoxib | |
BR0213536A (pt) | Formulações de xarope de ribavirina | |
ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
CY1115785T1 (el) | Μακροχρονια θεραπευτικη αγωγη συμπτωματικης καρδιακης ανεπαρκειας | |
WO2007145993A3 (en) | Modified compositions and methods for enhancing brain function | |
AU2003202550A1 (en) | Pharmaceutical formulations with modified release | |
PT1299114E (pt) | Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase | |
IT1303578B1 (it) | Composizione farmaceutica, in particolare di tipo dietetico ad azionemetabolica e termogenica utilizzabile nel trattamento del sovrappeso | |
BRMU8400102U (pt) | Instrumento especial para higienização bucal em geral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |